You might also like
ImmunityBio, Inc. (IBRX) is a biotechnology company dedicated to developing next-generation therapies and vaccines that enhance the natural immune system to combat cancers and infectious diseases. The company focuses on creating durable and safe protection against diseases by employing innovative immunotherapy platforms. Its offerings include biologic product candidates and approved treatments designed to activate both innate and adaptive immune responses.
-
Product Revenue - Includes sales of ANKTIVA, an FDA-approved IL-15 receptor superagonist antibody-cytokine fusion protein for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). ANKTIVA activates NK, CD8+, and memory T cells while avoiding immunosuppressive T-reg cell proliferation.
-
Other Revenues - Comprises income from non-exclusive license agreements related to cell lines, sales of bioreactors and related consumables, and grant programs.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Patrick Soon-Shiong ExecutiveBoard | Executive Chairman of the Board | Founder of NantWorks, LLC; Chairman of Chan Soon-Shiong Family Foundation | Patrick Soon-Shiong has been the Executive Chairman of the Board at IBRX since October 2020 and was appointed as Global Chief Scientific and Medical Officer on August 11, 2021. He has served on the IBRX board since 2014 and has helped shape the company’s strategic direction. | |
Richard Adcock ExecutiveBoard | Chief Executive Officer | CEO of ImmunityBio, Inc. since October 2020 and serves as President and Board Member since March 2021. Previously, he served as CEO of Verity Health System from January 2018 to September 2020 and held key leadership roles at Sanford Health and GE Healthcare. | View Report → | |
David Sachs Executive | Chief Financial Officer (CFO) | David Sachs is the Chief Financial Officer (CFO) of ImmunityBio, Inc. (IBRX) since March 9, 2021, and previously served as CFO of NantCell, Inc. from July 2019 to March 2021. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Ferring Pharmaceuticals | Competes in the context of NMIBC treatments, specifically with ImmunityBio's ANKTIVA platform. |
Competes in NMIBC treatments and cancer vaccine development. | |
Potential future competitor in NMIBC treatments. | |
Potential future competitor in NMIBC treatments. | |
Janssen Pharmaceuticals, Inc. | Potential future competitor in NMIBC treatments and also competes in CAR-T cell-based treatments. |
Potential future competitor in NMIBC treatments. | |
Competes in immunotherapy fusion protein development. | |
Neoleukin Therapeutics, Inc. | Competes in immunotherapy fusion protein development. |
Competes in immunotherapy fusion protein development and CAR-T cell-based treatments. | |
F. Hoffmann-La Roche AG | Competes in immunotherapy fusion protein development and cancer vaccine development. |
Competes in immunotherapy fusion protein development. | |
Competes in immunotherapy fusion protein development. | |
Achilles Therapeutics | Competes in cancer vaccine development. |
Competes in cancer vaccine development and T cell-based approaches. | |
Geneos Therapeutics, Inc. | Competes in cancer vaccine development. |
Hangzhou Neoantigen Therapeutics, Inc. | Competes in cancer vaccine development. |
Competes in cancer vaccine development and long COVID treatments. | |
Competes in NK cell-based approaches. | |
Catamaran Bio Inc. | Competes in NK cell-based approaches. |
Competes in NK cell-based approaches. | |
Competes in NK cell-based approaches. | |
Gamida Cell, Ltd. | Competes in NK cell-based approaches. |
Competes in NK cell-based approaches. | |
Competes in NK cell-based approaches. | |
Competes in NK cell-based approaches. | |
Shoreline Biosciences, Inc. | Competes in NK cell-based approaches. |
Competes in CAR-T cell-based treatments. | |
Competes in CAR-T cell-based treatments with two marketed products. | |
Competes in CAR-T cell-based treatments with two marketed products and HIV therapeutics. | |
Kite Pharma | Competes in CAR-T cell-based treatments. |
Competes in CAR-T cell-based treatments and long COVID treatments. | |
Poseida Therapeutics, Inc. | Competes in CAR-T cell-based treatments. |
Competes with an approved TIL therapy. | |
Competes with an approved TCR-T cell therapy. | |
Competes in T cell-based approaches. | |
Competes in T cell-based approaches. | |
Competes in T cell-based approaches. | |
Competes in T cell-based approaches. | |
Competes in T cell-based approaches. | |
ViiV Healthcare Limited | Competes in HIV therapeutics. |
Competes in long COVID treatments. | |
Laurent Pharmaceuticals | Competes in long COVID treatments. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Largest Customer #1 | Marketing & distribution of ANKTIVA | All | 38% of total FY 2024 revenue<br>~$5.61 million <br>(38% of $14.745 million ) |
Second Largest Customer #2 | Marketing & distribution of ANKTIVA | All | 29% of total FY 2024 revenue<br>~$4.28 million <br>(29% of $14.745 million ) |
Third Largest Customer #3 | Marketing & distribution of ANKTIVA | All | 25% of total FY 2024 revenue<br>~$3.69 million <br>(25% of $14.745 million ) |
Recent press releases and 8-K filings for IBRX.
- ImmunityBio, Inc. has requested an urgent meeting with the FDA to address the inconsistency between the unanimous guidance received during a January 2025 meeting to submit a supplemental BLA for NMIBC papillary disease and the subsequent Refusal to File (RTF) letter received on May 2, 2025.
- The company emphasizes the importance of resolving this regulatory discrepancy promptly to continue offering its promising ANKTIVA+BCG treatment, which showed strong clinical data in single-arm trials.
- ImmunityBio reported key clinical milestones for its ANKTIVA plus BCG therapy in bladder cancer, including a 71% complete remission rate in 100 patients, a durable complete response of 53 months, and high cystectomy‐free survival at 12, 24, and 36 months .
- The company filed a supplemental Biologics License Application (sBLA) in Q1 2025 to expand ANKTIVA plus BCG’s approved indication for treating BCG-unresponsive NMIBC papillary disease .
- An Expanded Access Protocol (EAP) was also submitted for ANKTIVA to treat lymphopenia, driven by robust regulatory momentum and unit sales growth .
- Key regulatory progress was further highlighted with the FDA’s expanded access authorization for a recombinant BCG in February 2025 .
- Global trials are rapidly enrolling in the USA, India, and South Africa, alongside efforts to overcome supply chain challenges and enhance immune activation .
- Financing Execution: ImmunityBio entered into a securities purchase agreement to raise approximately $75 million in gross proceeds, with an option for up to an additional $90 million through warrant exercise.
- Transaction Details: The offering involves the issuance of common stock along with warrants, structured as a registered direct offering to support ongoing business operations.
- Timing: The transaction, signed on April 7, 2025, is expected to close on or about April 9, 2025.
- Permanent J-code (J9028) issued in January 2025 spurred a 97% increase in ANKTIVA unit sales compared to December 2024.
- ANKTIVA sales in February 2025 grew 67% month-over-month, with the combined sales for January and February 2025 exceeding Q4 2024 totals (a 69% increase over November–December 2024).
- Q4 2024 financial results showed net product revenue of ~$7.2M, marking a 21% quarter-over-quarter improvement.